Drug details

Stivarga (regorafenib tablets)

type of Antineoplastic Tyrosine Kinase Inhibitors, Antineoplastics, Angiogenesis Inhibitor

Stivarga (regorafenib) is a kinase inhibitor used to treat patients with metastatic colorectal cancer (CRC).

This drug may have the following side effects:

• diarrhea,
• weakness,
• weight loss,
• stomach pain,
• tiredness,
• infection,
• high blood pressure (hypertension),
• weakness/fatigue,
• loss of appetite and decreased food intake,
• hand-foot skin reaction (HFSR),
• voice changes or hoarseness, and
• swelling, pain, and redness of the lining of your mouth, throat, stomach, and bowel.
  

The following drugs are related to Stivarga, either as a replacement or used together:

• Adrucil (fluorouracil injection)
• Alymsys (bevacizumab-maly injection)
• Avastin (bevacizumab)
• Camptosar Injection (irinotecan hydrochloride)
• Eloxatin (oxaliplatin injection)
• Lytgobi (futibatinib tablets)
• Sancuso (granisetron transdermal system)
• Imjudo (tremelimumab-actl injection)